Home » Healthcare » Pharmaceuticals » Human Insulin Market

Human Insulin Market

Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Human Insulin Market Size 2023	USD 21,000.00 Million
Human Insulin Market, CAGR	4.50%
Human Insulin Market Size 2032	USD 31,208.00 Million

Market Overview

Global Human Insulin Market size was valued at USD 21,000.00 million in 2023 and is anticipated to reach USD 31,208.00 million by 2032, at a CAGR of 4.50% during the forecast period (2023-2032).

The growth of the global human insulin market is driven by the rising prevalence of diabetes worldwide, increasing awareness about diabetes management, and advancements in insulin delivery technologies. A growing geriatric population, coupled with sedentary lifestyles and unhealthy dietary habits, has led to a surge in diabetes cases, thereby increasing the demand for insulin. Governments and healthcare organizations are also implementing supportive initiatives to improve access to insulin therapies, particularly in developing regions. Moreover, ongoing innovations such as smart insulin pens and continuous glucose monitoring systems are enhancing treatment adherence and outcomes, contributing to market expansion. The trend toward biosimilar insulin products is gaining momentum, offering cost-effective alternatives and fostering competitive pricing. Additionally, strategic collaborations and investments by key market players in research and development are accelerating the introduction of next-generation insulin formulations, further strengthening market growth. These factors collectively position the human insulin market for steady expansion over the forecast period.

The global human insulin market is influenced by a variety of geographical factors, with significant growth observed in North America, Europe, and the Asia-Pacific region. North America, driven by a high prevalence of diabetes and advanced healthcare infrastructure, remains a key market for insulin products. Europe follows closely, benefiting from well-established healthcare systems and increasing demand for biosimilar insulin. The Asia-Pacific region is witnessing rapid expansion due to the rising diabetic population, improving healthcare access, and growing affordability of insulin. Key players in the global human insulin market include Novo Nordisk A/S, Eli Lilly and Company, and Sanofi, which are leaders in insulin production and innovation. Other notable players such as Pfizer, Biocon, and MannKind Corporation contribute to market competition by offering diverse insulin formulations and advanced delivery systems. These companies are focusing on expanding their product portfolios and enhancing patient accessibility worldwide.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
The rising prevalence of diabetes worldwide is a major driver, with increasing demand for insulin therapies across all types of diabetes.
Technological advancements in insulin delivery systems, such as smart pens and insulin pumps, are shaping market trends.
The growing adoption of biosimilar insulin products is providing cost-effective alternatives, driving market competition.
Key players include Novo Nordisk, Eli Lilly, Sanofi, and other major pharmaceutical companies, focusing on innovation and strategic partnerships.
Market restraints include high production costs, regulatory complexities, and limited market penetration in certain developing regions.
North America holds the largest market share, followed by Europe and Asia-Pacific, with emerging markets in Asia fueling future growth.

Report Scope

This report segments the Global Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes Worldwide

One of the primary drivers fueling the global human insulin market is the rising prevalence of diabetes across the globe. For instance, the International Diabetes Federation estimates that the number of people living with diabetes will continue to rise significantly, with projections indicating a substantial increase in cases by 2045. Both Type 1 and Type 2 diabetes require insulin therapy for effective management, with Type 1 patients dependent on lifelong insulin administration. The increasing incidence of diabetes, particularly in emerging economies, is largely attributed to urbanization, lifestyle changes, poor dietary habits, and a growing aging population. This surge in diabetic cases continues to generate a consistent and growing demand for human insulin therapies.

Technological Advancements in Insulin Delivery

Technological innovation plays a vital role in propelling the growth of the human insulin market. For instance, advancements such as smart insulin pens, insulin pumps, and continuous glucose monitoring (CGM) systems are significantly improving the precision and convenience of insulin administration. These innovations not only enhance patient compliance but also reduce the risk of complications associated with poor glucose control. Furthermore, digital health solutions integrated with insulin delivery devices are allowing for personalized treatment and real-time monitoring, thereby elevating the standard of diabetes care. The adoption of these technologies is steadily rising in both developed and developing regions, further driving market growth.

Government Support and Health Initiatives

Governments and healthcare organizations across various countries are implementing robust initiatives to enhance diabetes care and expand access to insulin. Public awareness campaigns, funding for diabetes management programs, and subsidized insulin pricing are making treatment more accessible, especially in low- and middle-income countries. In addition, collaborations between public health bodies and private pharmaceutical firms are ensuring steady production and equitable distribution of insulin products. These efforts are aligned with global health goals to reduce the burden of non-communicable diseases, including diabetes, thereby reinforcing the demand for human insulin.

Growth of Biosimilars and Strategic Industry Collaborations

The emergence and growing acceptance of biosimilar insulin products are reshaping the competitive landscape of the human insulin market. Biosimilars offer more affordable alternatives to branded insulin, encouraging wider adoption, especially in cost-sensitive markets. This shift is driven by regulatory approvals and increasing trust among healthcare providers and patients. At the same time, major pharmaceutical companies are actively engaging in strategic partnerships, mergers, and acquisitions to expand their product portfolios and geographic reach. These collaborations are also accelerating research and development activities focused on creating next-generation insulin therapies, enhancing efficacy, and reducing side effects. As these industry dynamics evolve, they are collectively contributing to a robust and expanding human insulin market globally.

Market Trends

Increasing Adoption of Biosimilar Insulin

A significant trend shaping the global human insulin market is the growing adoption of biosimilar insulin products. For instance, Biocon Biologics recently received U.S. FDA approval for its biosimilar insulin, expanding accessibility for patients seeking cost-effective alternatives. As patents for originator insulin products expire, biosimilars are entering the market with competitive pricing and comparable efficacy. This shift is particularly impactful in emerging economies where affordability is a critical factor in healthcare access. As biosimilars gain wider acceptance among healthcare providers and patients, they are expected to drive market competition and improve accessibility to insulin therapies globally.

Strategic Collaborations and Global Market Expansion

Collaborations and strategic partnerships are becoming more prevalent as key players aim to expand their reach and strengthen their market positions. For instance, Vertex Pharmaceuticals secured an exclusive license for TreeFrog Therapeutics’ C-Stem technology to enhance the production of cell therapies for type 1 diabetes. Multinational pharmaceutical companies are entering alliances with biotech firms, research institutions, and digital health startups to develop innovative insulin products and delivery methods. Moreover, companies are increasing their focus on penetrating untapped markets in Asia, Africa, and Latin America, where the diabetic population is rising rapidly. These global expansion strategies, combined with a focus on innovation and affordability, are contributing to the dynamic evolution of the human insulin market landscape.

Integration of Digital Health Technologies

Digital health technologies are rapidly transforming diabetes management and influencing insulin market trends. Tools such as continuous glucose monitors (CGMs), mobile health applications, and connected insulin delivery devices are being integrated to create a more personalized and efficient care experience. These technologies enable patients to track their blood glucose levels in real-time, optimize insulin dosing, and receive remote guidance from healthcare providers. The integration of artificial intelligence (AI) and machine learning into digital platforms is further enhancing decision-making and adherence. As a result, the demand for tech-enabled insulin solutions is growing, particularly among younger and tech-savvy patient populations.

Shift Toward Patient-Centric and Personalized Therapy

The human insulin market is witnessing a shift toward more patient-centric and personalized approaches to treatment. Pharmaceutical companies are focusing on developing insulin formulations that offer flexible dosing schedules, faster onset of action, and longer duration to better match individual patient lifestyles. Ultra-rapid-acting and ultra-long-acting insulins are gaining popularity due to their convenience and improved glycemic control. Additionally, personalized insulin therapy based on genetic profiling and real-time health data is emerging as a promising trend, aiming to enhance treatment outcomes and reduce complications. This evolution reflects the broader movement toward precision medicine in chronic disease management.

Market Challenges Analysis

High Production Costs and Pricing Pressures

One of the key challenges facing the global human insulin market is the high cost associated with insulin production and pricing pressures from healthcare systems. For instance, a study published in BMJ Global Health highlights that the manufacturing process for insulin analogues involves complex biotechnological procedures, contributing to elevated production costs. The complex manufacturing process of insulin, which requires stringent quality controls and specialized infrastructure, contributes to its elevated production costs. In many countries, particularly in low- and middle-income regions, these costs translate into limited access and affordability for patients. Furthermore, growing scrutiny from governments and regulatory bodies around insulin pricing has led to increased pressure on pharmaceutical companies to reduce prices while maintaining quality and supply reliability. This tension between affordability and profitability poses a significant barrier to market expansion and equitable access to insulin therapies.

Regulatory Complexities and Limited Market Penetration in Developing Regions

Regulatory complexities and disparities across different regions also hinder the growth of the human insulin market. While developed nations benefit from streamlined approval processes and well-established regulatory frameworks, many developing countries face delays and inconsistencies in drug approvals, limiting timely access to newer insulin formulations. Additionally, inadequate healthcare infrastructure, lack of awareness, and low rates of diabetes diagnosis and management contribute to underutilization of insulin therapy in these markets. Logistics and cold-chain requirements for insulin storage further complicate distribution in remote and resource-constrained areas. Overcoming these regulatory and infrastructural barriers is critical for expanding the reach of insulin products and improving health outcomes for diabetic populations globally.

Market Opportunities

The global human insulin market presents significant growth opportunities, primarily driven by increasing demand in emerging economies. As the prevalence of diabetes rises in countries across Asia-Pacific, Latin America, and Africa, the need for accessible and affordable insulin therapies is becoming more urgent. These regions offer vast untapped potential due to their large populations, improving healthcare infrastructure, and rising awareness of chronic disease management. Governments in these areas are also implementing supportive policies and public health initiatives aimed at expanding access to essential medicines, including insulin. Pharmaceutical companies that strategically invest in localized manufacturing, cost-effective distribution networks, and tailored product offerings are well-positioned to gain a competitive edge and increase their market share in these high-growth regions.

Moreover, the market is poised to benefit from ongoing advancements in biotechnology and digital health solutions. Innovations in insulin formulation such as ultra-long-acting and rapid-acting analogs are enhancing patient adherence and glycemic control, while smart insulin delivery systems and connected healthcare platforms are transforming diabetes management. These developments provide opportunities for companies to differentiate their offerings and meet the growing demand for personalized, data-driven healthcare solutions. Additionally, the increasing acceptance of biosimilar insulin products offers a viable pathway to expand access and reduce treatment costs, particularly in price-sensitive markets. As regulatory frameworks continue to evolve and support biosimilar integration, manufacturers can capitalize on this trend to broaden their reach and address the global diabetes burden more effectively.

Market Segmentation Analysis:

By Device:

The global human insulin market is categorized by device type, including pens, syringes, and others. Among these, insulin pens are gaining significant market share due to their ease of use, portability, and precision in dosage delivery. Pens are increasingly popular among diabetic patients, especially for those requiring daily insulin injections, because of their user-friendly design and convenience. The demand for insulin pens is expected to grow in both developed and emerging markets as they offer greater accuracy compared to traditional syringes, reducing the likelihood of dosing errors. On the other hand, syringes remain an important device segment, particularly in regions where affordability is a priority, and insulin pens may be perceived as too expensive. While syringes are still widely used, the growing preference for pens is expected to gradually shift market dynamics. Other devices, such as insulin pumps and continuous glucose monitors (CGMs), are also contributing to market growth, especially in regions with advanced healthcare systems. These alternatives are being adopted for their ability to provide real-time insulin delivery and enhance patient compliance.

By Indication:

The global human insulin market is also segmented based on indications, including Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes holds a significant share of the market due to its prevalence and the necessity for lifelong insulin therapy. Patients with Type 1 diabetes rely on insulin for glucose regulation, making this segment the largest contributor to the overall market. As the incidence of Type 1 diabetes continues to rise globally, the demand for human insulin in this segment is expected to increase. In contrast, the market for Type 2 diabetes is experiencing substantial growth driven by the global rise in obesity rates, sedentary lifestyles, and aging populations. While Type 2 diabetes is often managed with oral medications initially, insulin therapy is required for more advanced stages, driving market demand. Gestational diabetes, although less common than the other two types, also represents a growing market segment, especially in regions where healthcare awareness and access are improving. Insulin therapy for gestational diabetes ensures proper glucose control during pregnancy, preventing complications for both mother and child, further expanding the market for human insulin in this area.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Russia
- Belgium
- Netherlands
- Austria
- Sweden
- Poland
- Denmark
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Thailand
- Indonesia
- Vietnam
- Malaysia
- Philippines
- Taiwan
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Peru
- Chile
- Colombia
- Rest of Latin America
Middle East
- UAE
- KSA
- Israel
- Turkey
- Iran
- Rest of Middle East
Africa
- Egypt
- Nigeria
- Algeria
- Morocco
- Rest of Africa

Regional Analysis

North America

North America holds the largest share of the global human insulin market, accounting for approximately 40% of the total market revenue. This dominance is primarily attributed to the high prevalence of diabetes, advanced healthcare systems, and the availability of a wide range of insulin products. The United States, in particular, leads the market due to its high diabetic population and significant investments in diabetes care. Moreover, the presence of major pharmaceutical companies and advanced insulin delivery devices, such as insulin pens and pumps, contributes to market growth. Additionally, the growing trend of health-consciousness and increasing adoption of digital health solutions, like continuous glucose monitoring systems, is fueling the demand for insulin in this region.

Europe

Europe holds the second-largest share in the global human insulin market, with a market share of around 25%. The demand for human insulin in this region is driven by the high incidence of Type 2 diabetes and an aging population. Countries like Germany, France, and the UK have well-established healthcare systems that provide easy access to insulin therapies, contributing to higher adoption rates. The region is also seeing a rise in the use of biosimilar insulin products, which has made insulin more affordable, further boosting market growth. Furthermore, technological innovations in insulin delivery devices, such as smart insulin pens, are gaining traction in Europe, driving growth within this segment.

Asia-Pacific

The Asia-Pacific region is experiencing rapid growth in the human insulin market, holding around 20% of the global market share. This is largely due to the rising prevalence of diabetes in countries such as China and India, where lifestyle changes, urbanization, and an increasing elderly population are contributing to a higher incidence of diabetes. With improving healthcare infrastructure and greater government initiatives focused on diabetes care, the demand for insulin is expected to rise steadily. Furthermore, the growing affordability of insulin products, including biosimilars, is making diabetes management more accessible to a larger population in the region. The Asia-Pacific market is expected to continue growing, with increased adoption of insulin pens and pumps.

Rest of the World

The rest of the world, encompassing regions such as Latin America, the Middle East, and Africa, accounts for approximately 15% of the global human insulin market. In these regions, there is a growing need for insulin due to the rising number of diabetes cases, particularly Type 2 diabetes. However, the market is challenged by limited access to healthcare and insulin products in certain areas, which can hinder growth. Despite these challenges, market opportunities are emerging as governments and international health organizations work to improve diabetes care. The rising number of healthcare initiatives aimed at improving access to essential medicines, including insulin, is expected to drive market growth in the coming years. Furthermore, the affordability and availability of biosimilar insulin are expected to positively impact the market in these regions.

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company

Competitive Analysis

The global human insulin market is highly competitive, with several key players dominating the landscape. Leading companies such as Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Pfizer, Biocon, MannKind Corporation, Wockhardt, Lupin, and Tonghua Dongbao Pharmaceutical Co. are at the forefront, contributing significantly to market growth. Companies are focusing on improving the efficiency and convenience of insulin administration, with advancements such as smart insulin pens, insulin pumps, and continuous glucose monitoring systems. These innovations are not only enhancing patient compliance but also providing more precise and personalized insulin management solutions. The competition in the market is also driven by the growing demand for biosimilar insulin products. As patents for original insulin products expire, many companies are entering the biosimilar market with cost-effective alternatives, thus increasing accessibility to insulin therapies, especially in price-sensitive regions. This is fostering a more competitive environment as both established and emerging companies focus on capturing market share in developing markets. Additionally, companies are increasingly forming strategic partnerships, collaborations, and mergers to enhance their market presence and extend their product portfolios. With an emphasis on expanding geographical reach, particularly in Asia-Pacific and Latin America, firms are focusing on improving distribution networks and ensuring better access to insulin therapies. The overall competitive landscape is dynamic, with innovation, affordability, and market penetration being key factors driving growth.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The global human insulin market is characterized by a moderate level of market concentration, with a few dominant players holding significant market shares, while several smaller companies and biosimilar manufacturers also contribute to the market’s diversity. The market is largely driven by major multinational pharmaceutical companies, which invest heavily in research and development to introduce innovative insulin products and delivery systems. However, the increasing presence of biosimilar insulin products is fostering greater competition, particularly in price-sensitive regions, by offering more affordable alternatives to patented insulin. The market is also influenced by the growing trend toward personalized and technology-driven diabetes care, with smart insulin pens and continuous glucose monitoring systems becoming more prevalent. Additionally, regional differences in healthcare infrastructure and access to insulin therapies contribute to market fragmentation, as companies tailor their products and strategies to meet local demands and regulatory requirements. Overall, the market is competitive, dynamic, and increasingly diverse.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The global human insulin market is expected to continue its steady growth due to the increasing prevalence of diabetes worldwide.
Biosimilar insulin products are anticipated to gain more market share, offering affordable alternatives and improving accessibility for patients.
Technological advancements in insulin delivery systems, such as insulin pens and pumps, will drive market innovation and patient adoption.
The growing trend toward personalized diabetes care will lead to more tailored insulin therapies based on individual needs.
The rising demand for digital health solutions, including continuous glucose monitoring systems, will enhance insulin management and treatment outcomes.
Emerging markets in Asia-Pacific, Africa, and Latin America will contribute significantly to the market’s expansion due to improving healthcare access.
Strategic partnerships and collaborations between pharmaceutical companies and technology firms will lead to more advanced insulin delivery systems.
Companies will continue to focus on reducing the cost of insulin, making therapies more accessible in both developed and developing regions.
The increasing focus on preventative healthcare and early diabetes detection will drive demand for insulin in the long term.
Regulatory advancements in biosimilar insulin approval and adoption will facilitate market growth and competition.

CHAPTER NO. 1 : INTRODUCTION 24
1.1.1. Report Description 24
Purpose of the Report 24
USP & Key Offerings 24
1.1.2. Key Benefits for Stakeholders 24
1.1.3. Target Audience 25
1.1.4. Report Scope 25
1.1.5. Regional Scope 26
CHAPTER NO. 2 : EXECUTIVE SUMMARY 27
2.1. Human Insulin Market Snapshot 27
2.1.1. Global Human Insulin Market, 2018 – 2032 (USD Million) 28
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 29
3.1. Russia-Ukraine and Israel-Palestine War Impacts 29
CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 30
4.1. Introduction 30
4.2. Market Drivers 31
4.2.1. Driving Factor 1 Analysis 31
4.2.2. Driving Factor 2 Analysis 32
4.3. Market Restraints 33
4.3.1. Restraining Factor Analysis 33
4.4. Market Opportunities 34
4.4.1. Market Opportunity Analysis 34
4.5. Porter’s Five Forces Analysis 35
4.6. Value Chain Analysis 36
4.7. Buying Criteria 37
CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 38
5.1. Import Analysis by Region 38
5.1.1. Global Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 38
5.2. Export Analysis by Region 39
5.2.1. Global Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 39
CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 40
6.1. Demand Analysis by Region 40
6.1.1. Global Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 40
6.2. Supply Analysis by Region 41
6.2.1. Global Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 41
CHAPTER NO. 7 : PRODUCTION ANALYSIS 42
7.1. Production Analysis by Region 42
7.1.1. Global Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 42
CHAPTER NO. 8 : PRICE ANALYSIS 43
8.1. Price Analysis by Region 43
8.1.1. Global Human Insulin Market Price, By Region, 2018 – 2023 43
8.1.2. Global Device Market Price, By Region, 2018 – 2023 43
8.2. Price Analysis by Device 44
8.2.1. Global Human Insulin Market Price, By Device, 2018 – 2023 44
8.2.2. Global Device Market Price, By Device, 2018 – 2023 44
CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 45
9.1. Key Raw Materials and Suppliers 45
9.2. Key Raw Materials Price Trend 45
CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 46
10.1. Manufacturing Cost Analysis 46
10.2. Manufacturing Process 46
CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 47
11.1. Company Market Share Analysis – 2023 47
11.1.1. Global Human Insulin Market: Company Market Share, by Volume, 2023 47
11.1.2. Global Human Insulin Market: Company Market Share, by Revenue, 2023 48
11.1.3. Global Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 48
11.1.4. Global Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 49
11.2. Global Human Insulin Market Company Volume Market Share, 2023 50
11.3. Global Human Insulin Market Company Revenue Market Share, 2023 51
11.4. Company Assessment Metrics, 2023 52
11.4.1. Stars 52
11.4.2. Emerging Leaders 52
11.4.3. Pervasive Players 52
11.4.4. Participants 52
11.5. Start-ups /SMEs Assessment Metrics, 2023 52
11.5.1. Progressive Companies 52
11.5.2. Responsive Companies 52
11.5.3. Dynamic Companies 52
11.5.4. Starting Blocks 52
11.6. Strategic Developments 53
11.6.1. Acquisitions & Mergers 53
New Product Launch 53
Regional Expansion 53
11.7. Key Players Product Matrix 54
CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 55
12.1. PESTEL 55
12.1.1. Political Factors 55
12.1.2. Economic Factors 55
12.1.3. Social Factors 55
12.1.4. Technological Factors 55
12.1.5. Environmental Factors 55
12.1.6. Legal Factors 55
12.2. Adjacent Market Analysis 55
CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY DEVICE SEGMENT ANALYSIS 56
13.1. Human Insulin Market Overview, by Device Segment 56
13.1.1. Human Insulin Market Revenue Share, By Device, 2023 & 2032 57
13.1.2. Human Insulin Market Attractiveness Analysis, By Device 58
13.1.3. Incremental Revenue Growth Opportunity, by Device, 2024 – 2032 58
13.1.4. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 59
13.2. Pens 60
13.2.1. Global Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61
13.2.2. Global Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61
13.3. Syringes 62
13.3.1. Global Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63
13.3.2. Global Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63
13.4. Others 64
13.4.1. Global Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65
13.4.2. Global Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65
13.5. Device 4 66
13.5.1. Global Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67
13.5.2. Global Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67
13.6. Device 5 68
13.6.1. Global Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69
13.6.2. Global Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69
CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY INDICATION SEGMENT ANALYSIS 70
14.1. Human Insulin Market Overview, by Indication Segment 70
14.1.1. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 71
14.1.2. Human Insulin Market Attractiveness Analysis, By Indication 72
14.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 72
14.1.4. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 73
14.2. Type 1 Diabetes 74
14.2.1. Global Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75
14.2.2. Global Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75
14.3. Type 2 Diabetes 76
14.3.1. Global Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77
14.3.2. Global Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77
14.4. Gestational Diabetes 78
14.4.1. Global Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79
14.4.2. Global Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79
14.5. Indication 4 80
14.5.1. Global Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81
14.5.2. Global Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81
14.6. Indication 5 82
14.6.1. Global Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83
14.6.2. Global Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83
CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY INSULIN SEGMENT ANALYSIS 84
15.1. Human Insulin Market Overview, by Insulin Segment 84
15.1.1. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 85
15.1.2. Human Insulin Market Attractiveness Analysis, By Insulin 86
15.1.3. Incremental Revenue Growth Opportunity, by Insulin, 2024 – 2032 86
15.1.4. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 87
15.2. Rapid-acting insulin 88
15.2.1. Global Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89
15.2.2. Global Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89
15.3. Short-acting insulin 90
15.3.1. Global Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91
15.3.2. Global Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91
15.4. Intermediate-acting insulin 92
15.4.1. Global Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93
15.4.2. Global Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93
15.5. Others 94
15.5.1. Global Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95
15.5.2. Global Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95
15.6. Insulin 5 96
15.6.1. Global Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97
15.6.2. Global Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97
CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 98
16.1. Human Insulin Market Overview, by Technology Segment 98
16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 99
16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 100
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 100
16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 101
16.2. Technology 1 102
16.2.1. Global Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103
16.2.2. Global Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103
16.3. Technology 2 104
16.3.1. Global Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105
16.3.2. Global Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105
16.4. Technology 3 106
16.4.1. Global Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107
16.4.2. Global Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107
16.5. Technology 4 108
16.5.1. Global Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109
16.5.2. Global Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109
16.6. Technology 5 110
16.6.1. Global Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111
16.6.2. Global Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111
CHAPTER NO. 17 : HUMAN INSULIN MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 112
17.1. Human Insulin Market Overview, by Distribution Channel Segment 112
17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 113
17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 114
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 114
17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 115
17.2. Hospital Pharmacies 116
17.2.1. Global Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117
17.2.2. Global Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117
17.3. Drug Stores and Retail Pharmacies 118
17.3.1. Global Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119
17.3.2. Global Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119
17.4. Online Providers 120
17.4.1. Global Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121
17.4.2. Global Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121
17.5. Distribution Channel 4 122
17.5.1. Global Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123
17.5.2. Global Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123
17.6. Distribution Channel 5 124
17.6.1. Global Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125
17.6.2. Global Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125
CHAPTER NO. 18 : HUMAN INSULIN MARKET – REGIONAL ANALYSIS 126
18.1. Human Insulin Market Overview, by Regional Segments 126
18.2. Region 127
18.2.1. Global Human Insulin Market Revenue Share, By Region, 2023 & 2032 127
18.2.2. Human Insulin Market Attractiveness Analysis, By Region 128
18.2.3. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 128
18.2.4. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 129
18.2.5. Global Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130
18.2.6. Global Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130
18.3. Device 131
18.3.1. Global Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131
18.4. Global Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131
18.5. Indication 132
18.5.1. Global Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132
18.5.2. Global Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132
18.6. Insulin 133
18.6.1. Global Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133
18.6.2. Global Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133
18.7. Technology 134
18.7.1. Global Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134
18.7.2. Global Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134
18.8. Distribution Channel 135
18.8.1. Global Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
18.8.2. Global Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135
CHAPTER NO. 19 : HUMAN INSULIN MARKET – NORTH AMERICA 136
19.1. North America 136
19.1.1. Key Highlights 136
19.1.2. North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137
19.1.3. North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138
19.1.4. North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139
19.1.5. North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140
19.1.6. North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141
19.1.7. North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142
19.2. U.S. 143
19.3. Canada 143
19.4. Mexico 143
CHAPTER NO. 20 : HUMAN INSULIN MARKET – EUROPE 144
20.1. Europe 144
20.1.1. Key Highlights 144
20.1.2. Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145
20.1.3. Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146
20.1.4. Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147
20.1.5. Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148
20.1.6. Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149
20.1.7. Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150
20.2. UK 151
20.3. France 151
20.4. Germany 151
20.5. Italy 151
20.6. Spain 151
20.7. Russia 151
20.8. Belgium 151
20.9. Netherland 151
20.10. Austria 151
20.11. Sweden 151
20.12. Poland 151
20.13. Denmark 151
20.14. Switzerland 151
20.15. Rest of Europe 151
CHAPTER NO. 21 : HUMAN INSULIN MARKET – ASIA PACIFIC 152
21.1. Asia Pacific 152
21.1.1. Key Highlights 152
21.1.2. Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153
21.1.3. Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154
21.1.4. Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155
21.1.5. Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156
21.1.6. Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157
21.1.7. Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158
21.2. China 159
21.3. Japan 159
21.4. South Korea 159
21.5. India 159
21.6. Australia 159
21.7. Thailand 159
21.8. Indonesia 159
21.9. Vietnam 159
21.10. Malaysia 159
21.11. Philippines 159
21.12. Taiwan 159
21.13. Rest of Asia Pacific 159
CHAPTER NO. 22 : HUMAN INSULIN MARKET – LATIN AMERICA 160
22.1. Latin America 160
22.1.1. Key Highlights 160
22.1.2. Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161
22.1.3. Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162
22.1.4. Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163
22.1.5. Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164
22.1.6. Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165
22.1.7. Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166
22.2. Brazil 167
22.3. Argentina 167
22.4. Peru 167
22.5. Chile 167
22.6. Colombia 167
22.7. Rest of Latin America 167
CHAPTER NO. 23 : HUMAN INSULIN MARKET – MIDDLE EAST 168
23.1. Middle East 168
23.1.1. Key Highlights 168
23.1.2. Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169
23.1.3. Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170
23.1.4. Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171
23.1.5. Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172
23.1.6. Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173
23.1.7. Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174
23.2. UAE 175
23.3. KSA 175
23.4. Israel 175
23.5. Turkey 175
23.6. Iran 175
23.7. Rest of Middle East 175
CHAPTER NO. 24 : HUMAN INSULIN MARKET – AFRICA 176
24.1. Africa 176
24.1.1. Key Highlights 176
24.1.2. Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177
24.1.3. Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178
24.1.4. Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179
24.1.5. Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180
24.1.6. Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181
24.1.7. Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182
24.2. Egypt 183
24.3. Nigeria 183
24.4. Algeria 183
24.5. Morocco 183
24.6. Rest of Africa 183
CHAPTER NO. 25 : COMPANY PROFILES 184
25.1. Novo Nordisk A/S 184
25.1.1. Company Overview 184
25.1.2. Product Portfolio 184
25.1.3. Swot Analysis 184
25.1.4. Business Strategy 185
25.1.5. Financial Overview 185
25.1.6. MannKind Corporation 186
25.1.7. Pfizer 186
25.1.8. Wockhardt 186
25.1.9. Biocon 186
25.1.10. Lupin 186
25.1.11. Tonghua Dongbao Pharmaceutical Co 186
25.1.12. Eli Lilly and Company 186
25.1.13. Company 9 186
25.1.14. Company 10 186
25.1.15. Company 11 186
25.1.16. Company 12 186
25.1.17. Company 13 186
25.1.18. Company 14 186
CHAPTER NO. 26 : RESEARCH METHODOLOGY 187
26.1. Research Methodology 187
26.1.1. Phase I – Secondary Research 188
26.1.2. Phase II – Data Modeling 188
Company Share Analysis Model 189
Revenue Based Modeling 189
26.1.3. Phase III – Primary Research 190
26.1.4. Research Limitations 191
Assumptions 191

List of Figures
FIG NO. 1. Global Human Insulin Market Revenue, 2018 – 2032 (USD Million) 30
FIG NO. 2. Porter’s Five Forces Analysis for Global Human Insulin Market 37
FIG NO. 3. Value Chain Analysis for Global Human Insulin Market 38
FIG NO. 4. Global Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 40
FIG NO. 5. Global Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 41
FIG NO. 6. Global Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 42
FIG NO. 7. Global Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 43
FIG NO. 8. Global Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 44
FIG NO. 9. Global Human Insulin Market Price, By Region, 2018 – 2023 45
FIG NO. 10. Global Human Insulin Market Price, By Device, 2018 – 2023 46
FIG NO. 11. Raw Materials Price Trend Analysis, 2018 – 2023 47
FIG NO. 12. Manufacturing Cost Analysis 48
FIG NO. 13. Manufacturing Process 48
FIG NO. 14. Company Share Analysis, 2023 49
FIG NO. 15. Company Share Analysis, 2023 50
FIG NO. 16. Company Share Analysis, 2023 50
FIG NO. 17. Company Share Analysis, 2023 51
FIG NO. 18. Human Insulin Market – Company Volume Market Share, 2023 52
FIG NO. 19. Human Insulin Market – Company Revenue Market Share, 2023 53
FIG NO. 20. Human Insulin Market Revenue Share, By Device, 2023 & 2032 59
FIG NO. 21. Market Attractiveness Analysis, By Device 60
FIG NO. 22. Incremental Revenue Growth Opportunity by Device, 2024 – 2032 60
FIG NO. 23. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 61
FIG NO. 24. Global Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 62
FIG NO. 25. Global Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 64
FIG NO. 26. Global Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 66
FIG NO. 27. Global Human Insulin Market for Device 4, Revenue (USD Million) 2018 – 2032 68
FIG NO. 28. Global Human Insulin Market for Device 5, Revenue (USD Million) 2018 – 2032 70
FIG NO. 29. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 73
FIG NO. 30. Market Attractiveness Analysis, By Indication 74
FIG NO. 31. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 74
FIG NO. 32. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 75
FIG NO. 33. Global Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 76
FIG NO. 34. Global Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 78
FIG NO. 35. Global Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 80
FIG NO. 36. Global Human Insulin Market for Indication 4, Revenue (USD Million) 2018 – 2032 82
FIG NO. 37. Global Human Insulin Market for Indication 5, Revenue (USD Million) 2018 – 2032 84
FIG NO. 38. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 87
FIG NO. 39. Market Attractiveness Analysis, By Insulin 88
FIG NO. 40. Incremental Revenue Growth Opportunity by Insulin, 2024 – 2032 88
FIG NO. 41. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 89
FIG NO. 42. Global Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 90
FIG NO. 43. Global Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 92
FIG NO. 44. Global Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 94
FIG NO. 45. Global Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 96
FIG NO. 46. Global Human Insulin Market for Insulin 5, Revenue (USD Million) 2018 – 2032 98
FIG NO. 47. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 101
FIG NO. 48. Market Attractiveness Analysis, By Technology 102
FIG NO. 49. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 102
FIG NO. 50. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 103
FIG NO. 51. Global Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 104
FIG NO. 52. Global Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 106
FIG NO. 53. Global Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 108
FIG NO. 54. Global Human Insulin Market for Technology 4, Revenue (USD Million) 2018 – 2032 110
FIG NO. 55. Global Human Insulin Market for Technology 5, Revenue (USD Million) 2018 – 2032 112
FIG NO. 56. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 115
FIG NO. 57. Market Attractiveness Analysis, By Distribution Channel 116
FIG NO. 58. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 116
FIG NO. 59. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 117
FIG NO. 60. Global Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 118
FIG NO. 61. Global Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 120
FIG NO. 62. Global Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 122
FIG NO. 63. Global Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 124
FIG NO. 64. Global Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 126
FIG NO. 65. Global Human Insulin Market Revenue Share, By Region, 2023 & 2032 129
FIG NO. 66. Market Attractiveness Analysis, By Region 130
FIG NO. 67. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 130
FIG NO. 68. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 131
FIG NO. 69. North America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 138
FIG NO. 70. Europe Human Insulin Market Revenue, 2018 – 2032 (USD Million) 146
FIG NO. 71. Asia Pacific Human Insulin Market Revenue, 2018 – 2032 (USD Million) 154
FIG NO. 72. Latin America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 162
FIG NO. 73. Middle East Human Insulin Market Revenue, 2018 – 2032 (USD Million) 170
FIG NO. 74. Africa Human Insulin Market Revenue, 2018 – 2032 (USD Million) 178
FIG NO. 75. Research Methodology – Detailed View 189
FIG NO. 76. Research Methodology 190

List of Tables
TABLE NO. 1. : Global Human Insulin Market: Snapshot 27
TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 31
TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 33
TABLE NO. 4. : Global Human Insulin Market Revenue, By Region, 2018 – 2023 43
TABLE NO. 5. : Global Human Insulin Market Revenue, By Device, 2018 – 2023 44
TABLE NO. 6. : Key Raw Materials & Suppliers 45
TABLE NO. 7. : Global Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61
TABLE NO. 8. : Global Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61
TABLE NO. 9. : Global Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63
TABLE NO. 10. : Global Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63
TABLE NO. 11. : Global Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65
TABLE NO. 12. : Global Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65
TABLE NO. 13. : Global Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67
TABLE NO. 14. : Global Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67
TABLE NO. 15. : Global Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69
TABLE NO. 16. : Global Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69
TABLE NO. 17. : Global Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75
TABLE NO. 18. : Global Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75
TABLE NO. 19. : Global Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77
TABLE NO. 20. : Global Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77
TABLE NO. 21. : Global Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79
TABLE NO. 22. : Global Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79
TABLE NO. 23. : Global Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81
TABLE NO. 24. : Global Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81
TABLE NO. 25. : Global Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83
TABLE NO. 26. : Global Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83
TABLE NO. 27. : Global Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89
TABLE NO. 28. : Global Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89
TABLE NO. 29. : Global Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91
TABLE NO. 30. : Global Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91
TABLE NO. 31. : Global Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93
TABLE NO. 32. : Global Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93
TABLE NO. 33. : Global Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95
TABLE NO. 34. : Global Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95
TABLE NO. 35. : Global Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97
TABLE NO. 36. : Global Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97
TABLE NO. 37. : Global Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103
TABLE NO. 38. : Global Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103
TABLE NO. 39. : Global Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105
TABLE NO. 40. : Global Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105
TABLE NO. 41. : Global Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107
TABLE NO. 42. : Global Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107
TABLE NO. 43. : Global Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109
TABLE NO. 44. : Global Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109
TABLE NO. 45. : Global Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111
TABLE NO. 46. : Global Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111
TABLE NO. 47. : Global Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117
TABLE NO. 48. : Global Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117
TABLE NO. 49. : Global Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119
TABLE NO. 50. : Global Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119
TABLE NO. 51. : Global Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121
TABLE NO. 52. : Global Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121
TABLE NO. 53. : Global Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123
TABLE NO. 54. : Global Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123
TABLE NO. 55. : Global Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125
TABLE NO. 56. : Global Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125
TABLE NO. 57. : Global Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130
TABLE NO. 58. : Global Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130
TABLE NO. 59. : Global Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131
TABLE NO. 60. : Global Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131
TABLE NO. 61. : Global Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132
TABLE NO. 62. : Global Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132
TABLE NO. 63. : Global Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133
TABLE NO. 64. : Global Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133
TABLE NO. 65. : Global Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134
TABLE NO. 66. : Global Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134
TABLE NO. 67. : Global Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
TABLE NO. 68. : Global Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135
TABLE NO. 69. : North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137
TABLE NO. 70. : North America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 137
TABLE NO. 71. : North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138
TABLE NO. 72. : North America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 138
TABLE NO. 73. : North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139
TABLE NO. 74. : North America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 139
TABLE NO. 75. : North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140
TABLE NO. 76. : North America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 140
TABLE NO. 77. : North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141
TABLE NO. 78. : North America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 141
TABLE NO. 79. : North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142
TABLE NO. 80. : North America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 142
TABLE NO. 81. : Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145
TABLE NO. 82. : Europe Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 145
TABLE NO. 83. : Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146
TABLE NO. 84. : Europe Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 146
TABLE NO. 85. : Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147
TABLE NO. 86. : Europe Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 147
TABLE NO. 87. : Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148
TABLE NO. 88. : Europe Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 148
TABLE NO. 89. : Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149
TABLE NO. 90. : Europe Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 149
TABLE NO. 91. : Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150
TABLE NO. 92. : Europe Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 150
TABLE NO. 93. : Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153
TABLE NO. 94. : Asia Pacific Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 153
TABLE NO. 95. : Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154
TABLE NO. 96. : Asia Pacific Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 154
TABLE NO. 97. : Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155
TABLE NO. 98. : Asia Pacific Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 155
TABLE NO. 99. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156
TABLE NO. 100. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 156
TABLE NO. 101. : Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157
TABLE NO. 102. : Asia Pacific Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 157
TABLE NO. 103. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158
TABLE NO. 104. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 158
TABLE NO. 105. : Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161
TABLE NO. 106. : Latin America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 161
TABLE NO. 107. : Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162
TABLE NO. 108. : Latin America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 162
TABLE NO. 109. : Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163
TABLE NO. 110. : Latin America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 163
TABLE NO. 111. : Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164
TABLE NO. 112. : Latin America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 164
TABLE NO. 113. : Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165
TABLE NO. 114. : Latin America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 165
TABLE NO. 115. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166
TABLE NO. 116. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 166
TABLE NO. 117. : Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169
TABLE NO. 118. : Middle East Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 169
TABLE NO. 119. : Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170
TABLE NO. 120. : Middle East Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 170
TABLE NO. 121. : Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171
TABLE NO. 122. : Middle East Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 171
TABLE NO. 123. : Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172
TABLE NO. 124. : Middle East Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 172
TABLE NO. 125. : Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173
TABLE NO. 126. : Middle East Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 173
TABLE NO. 127. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174
TABLE NO. 128. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 174
TABLE NO. 129. : Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177
TABLE NO. 130. : Africa Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 177
TABLE NO. 131. : Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178
TABLE NO. 132. : Africa Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 178
TABLE NO. 133. : Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179
TABLE NO. 134. : Africa Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 179
TABLE NO. 135. : Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180
TABLE NO. 136. : Africa Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 180
TABLE NO. 137. : Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181
TABLE NO. 138. : Africa Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 181
TABLE NO. 139. : Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182
TABLE NO. 140. : Africa Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 182

Frequently Asked Questions:

What is the current size of the Global Human Insulin?

The global human insulin market was valued at USD 21,000 million in 2023 and is expected to reach USD 31,208 million by 2032.

What factors are driving the growth of the Global Human Insulin?

Rising diabetes prevalence, technological advancements in insulin delivery, and expanding access to biosimilars are key growth drivers.

What are the key segments within the Global Human Insulin?

The market is segmented by device (pens, syringes), indication (Type 1, Type 2, gestational), insulin type, and distribution channel.

What are some challenges faced by the Global Human Insulin?

Challenges include high production costs, pricing pressure, and limited insulin access in some developing regions.

Who are the major players in the Global Human Insulin?

Key players include Novo Nordisk, Eli Lilly, Sanofi, Biocon, Pfizer, MannKind, Wockhardt, Lupin, and Tonghua Dongbao.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –